BioSpace News Archive

POXEL SA announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.

Insightec announced the publication of the largest prospective, long-term follow-up study of unilateral MRI-guided focused ultrasound thalamotomy for essential tremor to date.

MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, announced the company’s scientific and management team’s participation in several scientific and investor conferences in November.

EdiGene, Inc. announced its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass.

Every year, approximately 8 million Americans are susceptible to dangerous, often fatal blood clots when they are admitted to the hospital for a medical illness such as stroke or an infection like COVID-19.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the presentation of new data from the Phase 3 RAPID clinical trial of etripamil, the Company’s investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for AT-GAA.

AbbVie (NYSE: ABBV) today announced new results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation (POAF) in cardiac surgery patients.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it will participate in the Guggenheim 4th Annual Immunology and Neurology Day, November 14th and 15th.

Mirum Pharmaceuticals, Inc., presented new data from LIVMARLI® oral solution studies, including two late-breaker presentations, at The Liver Meeting® of the American Association for the Study of Liver Diseases taking place November 4-7, 2022 in Washington, D.C.